Citations

Clear

3042 citation(s) found for "Kumar, S".

Impact of Novel Agents on Young Patients with t(11;14) Multiple Myeloma
Vallumsetla, Nishanth, Kumar, Shaji , Lacy, Martha Q. , Painuly, Utkarsh , Kyle, Robert A. , Kapoor, Prashant , Paludo, Jonas , Ketterling, Rhett P. , Gertz, Morie A. , Dispenzieri, Angela , Buadi, Francis K. , Dingli, David , Leung, Nelson , Rajkumar, S. Vincent

Mayo Clinic

Blood | October 10, 2019 | Volume: 124 | Issue: 21 | Pages: 2059-2059

10.1182/blood.v124.21.2059.2059 Get It

Abstract Background: Outcome studies for the unique cohort of young patients with multiple myeloma (MM) are sparse. In general, MM is a heterogenous disease with the genetic signature being one of the major determinants of prognosis. We have recently reported on improvement in overall survival (OS) of young patients with the use of novel agents, but the maximal survival gain has been achieved by integrating autologous stem cell transplant (SCT) to our current approach. Herein, we report on outcomes of patients with MM who were 50 years or younger at diagnosis and stratified by fluorescence in situ hybridization (FISH) results. Our study focuses on t(11;14) myeloma as its prognostic impact remains unclear with the use of novel agents upfront. Methods: Out of 1384 patients with MM, evaluated consecutively at Mayo Clinic, Rochester, MN between 1/1/2000 and 12/31/2011, 290 (21%) were 50 years or younger at diagnosis. Interphase FISH, performed within 100 days of diagnosis of MM, was utilized to stratify patients as high-risk [deletion 17p, t(14;16), t(14;20) or t(4;14)] or standard-risk [normal FISH, trisomies, t(11;14), t(6;14) or monosomy13/deletion 13q]. FISH results were available in 125 young patients that comprise the cohort of interest in the current study. OS from diagnosis was estimated by the Kaplan-Meier method. Results: Median age at diagnosis of MM was 47 years (range: 22 to 50 years) and 58% of the patients were male. At the time of data cut-off (7/31/2014), 45 (36%) patients had died with 90% of all known causes of deaths (n=39) being MM related. FISH abnormalities were noted in 114 (91%) patients. At diagnosis, 46%, 30% and 24% patients were categorized as International Staging System (ISS) stage I, II and III, respectively. The estimated median follow up was 60 months (95% CI: 54-67) and the 5-year OS rate was 69% [median 86 months (95% CI: 76-108)]. Standard (n=100; 80%) and high (n=25; 20%) risk patients had a median OS of 89 months (95% CI: 76-108) and 77.6 months (95% CI: 42-130), respectively (p=0.87). In order to further investigate the similar outcomes between these broad risk-groups with typically diverse disease course, we assessed the outcomes based on the common genetic abnormalities (Table 1) within each of the 2 categories. Presence of t(11;14) (n=37; 29%) was associated with a significantly shorter median OS (76 months) compared to patients with trisomic and normal FISH profile (n=46) (91 months, p=0.01; Figure 1). Patients with t(11;14) also had a significantly shorter median OS compared to those with other standard-risk FISH abnormalities (median OS 96 months, p=0.02). Presence of t(11;14) was not associated with higher plasma cell labeling index (PCLI, p=0.29) or worse ISS stage (p=0.99) compared to patients without t(11;14). OS survival of patients with t(11;14) was similar to those with high risk features (median 76.2 vs. 77.6 months, p=0.32). Of 24 (65%) patients with t(11;14) who underwent SCT, 79% had early SCT (within 12 months from diagnosis). Median OS was 79.4 months (95% CI: 36-108) vs. not reached (NR) (95% CI: 27-NR), respectively (p=0.79) in early versus late SCT. Twenty-one (57%) and 13 (35%) patients with t(11;14) received initial immunomodulatory drugs or bortezomib-based therapies, respectively. Those receiving frontline bortezomib had a higher median OS (76.2 months, 95% CI 76-79) compared to 64.8 months (95% CI 32-108) with other initial agents although it did not reach statistical significance (p=0.78). Conclusion: Presence of t(11;14) is associated with an inferior OS compared to patients with normal FISH, trisomies, or other standard risk abnormalities in young patients with MM. Given, the inherent biases associated with a retrospective study from a referral institution, our findings require external validation. However, our data suggest that our current therapeutic approaches in managing young patients with this unique genetic signature are inadequate. Table 1FISHn(%)Median OS in months (95% CI)t(11;14)37(29)76.2 (53.5-107.7)Trisomies35(28)91.3 (76.4-NR)13/del(13q)11(9)NR (32-NR)Normal11(9)95.5 (45.4-95.6)t(4;14)11(9)NR (40.1-NR)del(17p)/-1710(8)42 (19.2-129.6)t(14;16)4(3)77.6 (42.4-NR)Others6(5)NR (11.5-NR) Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.
Delays in Start of Intensification Therapy Are Common for Adults with Acute Lymphoblastic Leukemia, and Are Associated with Decreased Survival in Patients Who Undergo Allogeneic Stem Cell Transplant (SCT)
Kumar, Anita J. , Gimotty, Phyllis A. , Buck, Georgina , Rowe, Jacob M. , Goldstone, Anthony H., Marks, David I. , Litzow, Mark R. , Paietta, Elisabeth , Tallman, Martin S. , Luger, Selina M. , Loren, Alison W. , Gelfand, Joel M. , Fielding, Adele K. , Lazarus, Hillard M.

Mayo Clinic

Blood | October 10, 2019 | Volume: 124 | Issue: 21 | Pages: 208-208

10.1182/blood.v124.21.208.208 Get It

Abstract Acute lymphoblastic leukemia (ALL) has a high relapse rate in adults. While the biology of the patient may be responsible for the marked difference in survival seen in comparison to children, variable adherence to complex chemotherapy regimens may also play a role. However, there is very little understanding about the risk factors for delays in therapy and the impact of delays on survival. To study delays in newly diagnosed adult ALL patients, we conducted an observational study using data from ECOG 2993/ MRC_UKALLXII (Rowe, Blood 2005). We analyzed Ph- patients who started intensification after documented complete remission (CR). A long delay (LD) was defined as > 98 days from start of induction to start of intensification (IS), which was >2 weeks delay beyond the 84 days recommended per protocol. A Very Long Delay (VLD) was defined as a >4 weeks delay. Of 2109 patients enrolled, 1247 patients met inclusion criteria for analysis. Of note, 435 Ph- patients who achieved CR after induction but did not proceed to intensification were excluded. In univariate analysis, female sex (p<0.001), Black race (p=0.01), and older age (p<0.001) were associated with increased odds of LD. During induction presence of infection (p=0.01), dose reductions (p=0.001), duration of neutropenia (p=0.007), thrombocytopenia (p<0.001), and hospitalization duration (p<0.001) were associated with LD. In multivariate regression, age, female sex, dose reduction, Black race, and hospitalization duration were significantly associated with LD and VLD (Table I). At 2 years after diagnosis, 801/1247 (64.2%) patients were alive. Of the surviving patients, 181 (22.5%) had VLD, and 620 (77.4%), had delay <4 weeks, p=0.073. Of the alloHCT patients, 333 were alive: 57/333 (17%) had VLD, and 276/333 (83%) had been delayed <4 weeks (p=0.036). As of July 2014, 687/1247 (55%) patients have died, with a median time to death from start of intensification of 13.3 months (range 0.8-231). Survival analysis was stratified by post-remission therapy, with living patients censored at date last seen. Patients who received myeloablative allogeneic HCT (allo HCT) had poorer overall survival from start of intensification (OS-IS) and event free survival (EFS-IS) after LD or VLD. While OS-IS and EFS-IS were significantly worse for alloHCT patients after VLD (p=0.02 and p=0.03) respectively, survival was not worse for non-transplant patients after VLD (p=0.24 and p=0.10) (Figure I). In a multivariate Cox regression, adjusting for other high-risk disease features (age, cell lineage, and white cell count at diagnosis), patients who underwent allo HCT had significantly worse OS-IS (HR 1.4, p=0.02) and EFS-IS (HR 1.4, p=0.02) after experiencing VLD compared to alloHCT patients who experienced <4 weeks delay. When evaluating OS and EFS from diagnosis, VLD was still associated with poorer OS (HR 1.34, p=0.04) and EFS (HR 1.34, p=0.03). There was no difference in OS or EFS in patients who received non-transplant post-remission therapy based on delay. In a comprehensive analysis of the largest adult ALL study ever reported, we identified significant risk factors predictive of LD and VLD (>2 and >4 weeks beyond mandatory rest period). Our findings highlighted that patients were delayed because of chemotherapy toxicity and also identified healthcare disparities. VLD was associated with poorer OS and EFS in patients undergoing alloHCT, but not in patients undergoing non-transplant post remission therapy. Further studies are planned to prospectively identify patient barriers to on-schedule treatment with a goal of earlier intervention. The ability to better predict and intervene on risk factors for delay can improve adherence to protocol and optimize long-term survival. Table I: Multivariate Regression for LD and VLD Risk Factors Variable Odds Ratio 95% Confidence Interval p-value Days in the hospital Phase I Induction 1.01 1.00-1.02 0.04 Duration of Thrombocytopenia, Phase I 1.02 1.01-1.03 0.001 Age by Decade 1.2 1.08-1.31 <0.001 Reduced Dose in Induction 1.54 1.08-2.22 0.019 Sex, Female 1.56 1.22-2.0 <0.001 Race, Black 3.4 1.41-7.96 0.006 Figure 1 Figure 1. p=0.023 Disclosures No relevant conflicts of interest to declare.
Development and Results of a Multiple Myeloma Specific Custom 77-Gene Mutation Panel for Clinical Targeted Sequencing
Kortuem, K. Martin, Stewart, A. Keith, Bruins, Laura A., Ahmann, Gregory , Vasmatzis, George , Kumar, Shaji , Lacy, Martha Q. , Champion, Mia D., Rajkumar, S. Vincent , Dispenzieri, Angela , Gertz, Morie A. , Fonseca, Rafaël , Bergsagel, P. Leif , Braggio, Esteban

Mayo Clinic

Blood | October 10, 2019 | Volume: 124 | Issue: 21 | Pages: 169-169

10.1182/blood.v124.21.169.169 Get It

Abstract Background:A goal of “post-genomic” cancer care is development of specific, affordable, reliable and rapid next-generation sequencing-based assays determining prognosis, therapeutic selection and minimal disease monitoring, replacing older technologies in the diagnostic and monitoring workup. In this regard, we designed and deployed a custom gene panel for identification of mutations, copy-number changes and clonal frequency in multiple myeloma (MM) samples. Methods: The MM Mutation Panel Version 2.0 (M3P 2.0)1 includes 1271 amplicons from 77 genes that are either mutated in MM (genes with a published mutation incidence ≥3%), represent critical pathophysiological pathways, are targetable with small molecule-based therapies and/or are associated with drug resistance (eg. XBP-1, CRBN, IZKF, IRF4). The amplicons are spread across 21 chromosomes, allowing the identification of copy-number changes in these regions. Results: We have sequenced 38 MM cases (150 will be presented) with paired tumor-germline DNA samples, using only 20ng of DNA for library preparation. Patients (Pts) included 29 untreated and 9 MM pts with multi drug refractory disease. Coverage depth averaged 964X. Hyperdiploid MM was successfully identified in 45% of cases, del(13q) in 34%, del(1p) in 18%, del(17p) in 8% and gain of 1q in 13%. Array CGH in representative cases confirmed concordance with semiconductor sequencing. Overall, 71 exonic missense and 3 nonsense mutations were detected, and 7 frameshift indels. In 89% of the pts a mutation in at least one M3P2.0 gene was identified (range 1-8). 92% of mutations were predicted damaging (Provean, Polyphene-2 or SIFT). Most commonly mutated were KRAS (37%), NRAS (21%), BRAF (13%), TP53, CDKN1B, DIS3 (each 11%), FAM46C, STAT3, and IRF4 (each 8%). The MEK-ERK pathway was mutated in 61% of cases and in 3 cases more than one gene in this pathway (NRAS, KRAS, BRAF) was simultaneously mutated. Six mutations in BRAF were identified in 5 untreated pts, 3 of them known to be activating and targetable (Val600E). Other commonly mutated pathways were the NFKB pathway in 24% of pts and the Cyclin D pathway, mutated in 16% of cases. Genes of the cereblon pathway (CRBN, IRF4, IKZF3), essential for the action of lenalidomide (len) were mutated in 5 Pts. One newly diagnosed and len refractory Pt harbored a subclonal CRBN mutation (Asn316Lys, allelic fraction [AF] 20%) as well as 4 clonal IRF4 mutations within the DNA binding domain of the gene (Lys89Asn (AF 78%), Lys77Glu, Ser48Arg and Cys49Ser (AF 80% each). Another IRF4 mutated (Lys123Arg, AF 90%) hemodialysis dependent Pt was responsive to dose adapted treatment of len and dexamethasone (dex). Mutations in the C2H2-type 3 region of IKZF3 in a len resistant (Gly191Arg, AF 48%) pt occured as well as in a len and dex responsive (Arg242Gly, AF 52%) Pt. Furthermore, we identified a truncating XBP1 mutation (p.Leu232*, 97% AF) in a Pt refractory to bortezomib. One patient harbored a mutation in the steroid receptor NR3C1 (Pro255Leu, 22% variant reads). Finally, integrated mutation and copy-number data identified biallelic deletions of CDKN2C and FAM46C in a multi drug refractory Pt. Mutation and/or copy-number losses in both alleles were found in DIS3 in 4 Pts, in CYLD, TP53 and TRAF3 in 2 Pts and in CARD11, CDKN2A, CDKN1B, RB1and STAT3 in one Pt each. Conclusion: In summary, we report the initial results from 38 MM Pts using a custom MM sequencing panel which employs small amounts of DNA requiring very few cells and providing deep coverage in clinically meaningful timeframes. Our findings frequently include prognostically significant information, actionable targets and mutations in genes related to drug resistance. Targeted mutation profiling will likely become part of the clinical workup in MM and our M3P2.0 mutation panel is a suitable tool to provide information needed to guide precision therapy and to set the basis for individually tailored treatment decisions. 1. Kortuem KM. et al. Development Of a 47 Gene Sequencing Panel For Common Mutations Present In Multiple Myeloma: Preliminary Results In 77 p53 Deleted Patients, ASH 2013. Disclosures Stewart: Celgene: Consultancy; Bristol Myers Squibb: Consultancy; Array BioPharma: Consultancy; Sanofi: Consultancy; Takeda Pharmaceuticals International Co.: Research Funding; Novartis: Consultancy. Bruins:OncoSpire: Salary support Other. Vasmatzis:OncoSpire: Salary Support Other. Kumar:Celgene: Consultancy, Research Funding; Millennium: The Takeda Oncology Co.: Consultancy, Research Funding; Onyx Pharmaceuticals: Consultancy, Research Funding; Sanofi-Aventis: Consultancy, Research Funding; Array BioPharma: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Skyline Diagnostics: Membership on an entity's Board of Directors or advisory committees. Fonseca:Medtronic, Otsuka, Celgene, Genzyme, BMS, Lilly, Onyx, Binding Site, Millennium, AMGEN: Consultancy, patent for the prognostication of MM based on genetic categorization of the disease. He also has sponsored research from Cylene and Onyx Other, Research Funding. Bergsagel:MundiPharma: Research Funding; OncoEthix: Research Funding; Constellation Pharmaceutical: Research Funding; Novartis: Research Funding.
N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM)
Merlini, Giampaolo , Lacy, Martha Q. , Baudi, Francis K., Kumar, Shaji , Hayman, Suzanne R. , Lust, John A., Kapoor, Prashant , Zeldenrust, Steven R., Hwa, Yi L. , Kyle, Robert A. , Merlini, Giampaolo , Milani, Paolo , Gertz, Morie A. , Palladini, Giovanni , Leung, Nelson , Dingli, David , Lin, Yi , Go, Ronald S. , Rajkumar, S. Vincent , Dispenzieri, Angela

Mayo Clinic

Blood | October 10, 2019 | Volume: 126 | Issue: 23 | Pages: 3292-3292

10.1182/blood.v126.23.3292.3292 Get It

Abstract Background: Both MM specific and patient specific parameters place patients at risk for death. Patient frailty has been delineated primarily by age and ECOG performance score (PS) and secondarily with creatinine, eGFR, and the International Staging System (ISS), which reflect both renal function and disease burden. In an attempt to improve upon these commonly used measures, a frailty score for elderly patients that combines functional status [Activity of Daily Living (ADL) and Instrumental Activity of Daily living scores], comorbidities [Charlson comorbidity index (CCI)] and age has been developed by the IMWG. Incorporation of these tools into a busy clinical practice is challenging due to time constraints. Therefore, the identification of frail patients with an easily applicable, rapid and objective tool remains a challenge and an unmet need. A reliable, non-invasively assessable, biochemical marker of frailty would be an ideal tool to identify patients at higher risk of death. It was our goal to determine the role of NT-proBNP, a well-established cardiovascular risk biomarker, as a marker of frailty in patients with MM and in predicting overall survival (OS). Methods: Patients were elegible for this retrospective study if they were seen at the Mayo Clinic, Rochester, MN within 30 days of their myeloma diagnosis during the interval between 1/1/2007 and 12/31/2011. As part of the Mayo Clinic registration, all patients complete forms containing their past medical history, symptoms, and ADLs. Data from that first visit was abstracted and used to calculate a CCI. We excluded all patients with a concomitant diagnosis of light-chain AL amyloidosis. NT-proBNP concentration was measured in frozen sera collected within 30 days of diagnosis. NT-proBNP assay was run on the E170 Modular analyzer (Roche Diagnostics, Penzberg, Germany). We evaluated the prognostic role of NT-proBNP and these indices on OS using the Kaplan-Meier method. Results: Among the 351 consecutive patients satisfying entry criteria, median age was 65 years (range 22-95), 33% were ≥70 years, and 56% were male. Twenty-eight percent were ISS stage III, 13% had a creatinine ≥2 mg/dL, 19% had PS ≥2, and 11% had ADL score ≥2, and 30% CCI ≥2. The median value of NT-proBNP was 109 ng/L (interquartile range: 30-375 ng/L). NT-proBNP concentrations differed in the three ISS stages (median: 122 ng/L stage I, 190 ng/L stage II and 1822 ng/L stage III, P<0.0001). Median OS was 5.6 years. The best cutoff of NT-proBNP predicting OS at one year was 301 ng/L (sensitivity: 57.88%, specificity: 74.29%; AUC=0.668) and distinguished two groups with different OS (median not reached vs. 35 months, P<0.0001). Variables predictive for OS are shown in the Table and included PS, age, CCI, ISS, NT-proBNP. On multivariate analysis, ISS and NT-proBNP were independent of each other as long as age, PS and/or CCI were excluded from the model. NT-proBNP withstood these clinical variables better than did ISS (data not shown). We built two different models (table). In model 1, NT-proBNP >301 ng/L was an independent predictor of survival while age ≥70 and PS ≥2 and CCI were not significant. However, if we considered ISS stage instead of NT-proBNP in the same model, ISS stage was not significant. Conclusions: In this unselected cohort of patients with newly diagnosed multiple myeloma, NT-proBNP was a useful predictor of survival independent of age and PS. The threshold of 301 ng/L is remarkably similar to the well-established cutoff for heart failure of 300 ng/L. NT-proBNP outperformed the CCI and the ISS as risk factors. NT-proBNP is a widely available biomarker that could be added to the panel of laboratory tests of newly diagnosed MM patients and serve as a simple means of determining patient frailty in a busy clinical practice. Table. Results of univariate and multivariate analysis of various prognostic factors (NS, not significant; NI, not included). Univariate Multivariate Multivariate RR (95% CI) P Model 1 P Model 2 P PS ≥2 3.4 (2.4-4.8) <0.0001 2.5 (1.7-3.6) <0.0001 2.8 (1.9-4.0) <0.0001 Age ≥70 2.7 (1.9-3.6) <0.0001 2.1 (1.5-2.9) <0.0001 1.9 (1.3-2.7) 0.0003 CCI >=2 1.9 (1.4-2.6) <0.0001 NS NS 1.5 (1.0-2.0) 0.03 ISS stage 1.1 (1.1-1.8) 0.0004 NI NI NS NS NT-proBNP >301 ng/L 2.3 (1.7-3.2) <0.0001 1.6 (1.1-2.2) 0.007 NI NI Disclosures Merlini: Janssen-Cilag: Honoraria; Prothena: Honoraria; Millennium-Takeda: Honoraria; Pfizer: Honoraria. Kumar:Janssen: Research Funding; Celgene: Research Funding; Sanofi: Research Funding; Millenium/Takeda: Research Funding; AbbVie: Research Funding; Onyx: Research Funding; Celgene, Millenium, Sanofi, Skyline, BMS, Onyx, Noxxon,: Other: Consultant, no compensation,; Skyline, Noxxon: Honoraria.
Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicing Outcome in 345 Patients
Lacy, Martha Q. , Kumar, Shaji , LaPlant, Betsy, Laumann, Kristina, Hayman, Suzanne R. , Lust, John A., Zeldenrust, Steven R., Stewart, Keith, Sher, Taimur , Chanan‐Khan, Asher , Reeder, Craig B. , Gertz, Morie A. , Buadi, Francis K. , Dispenzieri, Angela , Dingli, David , Fonseca, Rafaël , Bergsagel, P. Leif , Roy, Vivek , Rajkumar, S. Vincent , Mıkhael, Joseph

Mayo Clinic

Blood | October 10, 2019 | Volume: 120 | Issue: 21 | Pages: 201-201

10.1182/blood.v120.21.201.201 Get It

Abstract Abstract 201 Background: Pomalidomide at doses of 2 or 4 mg/d has demonstrated excellent activity in patients with relapsed multiple myeloma (MM). Between November 2007 and March 2012, we opened 6 sequential phase 2 trials and treated 345 patients with relapsed MM with pomalidomide at differing doses with weekly dexamethasone (Pom/dex). Results of 164 of these patients have been previously published. Here we describe long term follow up of these patients as well as results of an additional 181 patients with relapsed MM treated with the Pom/dex regimen. Methods: The six cohorts consisted of: Cohort 1 (N=60): relapsed MM with 1–3 prior regimens, 2 mg dose; Cohort 2 (N=34): lenalidomide (LEN) refractory, 2 mg dose; Cohort 3 (N=35): BZ)/LEN refractory, 2 mg dose; Cohort 4 (N=35): BZ/LEN refractory, 4 mg dose; Cohort 5 (N=60) LEN refractory, 1–3 prior regimens, 4 mg dose; and Cohort 6 (N=120) LEN refractory, 4 mg dose. Pomalidomide was given orally 2 mg daily or 4mg daily on days 1–28(cohorts 1–5) or 1–21 (cohort 6) of a 28-day cycle with oral dexamethasone given 40 mg daily on days 1, 8, 15 and 22. Response was assessed by the International Myeloma Working Group Uniform Response criteria. All patients received aspirin 325 mg daily for deep venous thrombosis (VTE) prophylaxis or full dose anticoagulation. Results: A total of 345 patients were enrolled across all 6 cohorts. One patient was ineligible and excluded from analysis. The median age was 64 years (32–88). The median time since diagnosis was 53 months. The median number of prior therapies was 3 (1–14). 147 (44%) had high-risk molecular markers by mSMART criteria. Prior therapies consisted of thalidomide 52%, lenalidomide 87%, bortezomib 75%, autologous stem cell transplant 70% and allogeneic transplant 3%. The median follow-up is 10.4 months (5.4–34 months). Sixty-seven percent are alive and 32% remain progression free. 46 patients are continuing to receive treatment. The most common toxicities (grade 3 or higher) were neutropenia (31%), anemia (16%), thrombocytopenia (12%), pneumonia (8%) and fatigue (8%). VTE was seen in 10 patients (3%). Outcomes are shown in Table 1. Across all 6 cohorts confirmed responses of partial response (PR) or better were seen in 34%. The response rate in all patients with mSMART high risk status was 30.6%. Responses and duration of response (DOR) in those with high risk molecular markers include: 17p– 19 of 56 (34%) DOR 8.2 months; t(4;14) 6 of 24 (25%) and DOR 4.8 months; t(14;16) 7 of 11(64%) and DOR 9.5 months; deletion 13 by cytogenetics 13 of 37 (35%) with DOR 8.2 months. In a multivariate analysis, only LDH > ULN, number of prior regimens, and prior BZ therapy were predictive of a shorter TTP and factors associated with a poor OS following initiation of pomalidomide therapy included B2M > 5.5, LDH > ULN,number of prior regimens, and prior BZ therapy. Conclusions: Pom/dex is active and well tolerated even in heavily pretreated patients and those with high risk molecular markers. Remissions are durable. Response rates and toxicity are similar between the 2 mg and 4 mg doses. Disclosures: Lacy: Celgene: Research Funding. Stewart:Celgene: Consultancy, Honoraria. Reeder:Celgene: Mayo Clinic receives funding from Celgene to support clinical trials Other, Research Funding.
Enteropathy-Associated T-Cell Lymphoma in the U.S.: A Population-Based Study Using Surveillance, Epidemiology, and End Results Program and National Cancer Data Base
Karanam, Pawan Kumar, Al‐Hamadani, Mohammed , Ansell, Stephen M. , Go, Ronald S.

Mayo Clinic

Blood | October 10, 2019 | Volume: 124 | Issue: 21 | Pages: 1631-1631

10.1182/blood.v124.21.1631.1631 Get It

Abstract Background: Enteropathy-associated T-cell lymphoma (EATL) is a very rare primary intestinal non-Hodgkin lymphoma (NHL) strongly associated with celiac disease. Previous studies suggest that EATL may be more common in Europe and among white population, in which celiac disease is a prevalent condition. However, comparative racial epidemiologic study of EATL in a large population is lacking and clinical studies remain limited to small series. Using two U.S. population databases, we determined the comparative incidences according to race and described the clinical features and outcome of the largest series of EATL reported to date. Methods: Incidence rates (case/1,000,000) were calculated using 2000-2010 data from the Surveillance, Epidemiology, and End Results (SEER) Program and age-adjusted to the U.S. 2000 standard population. Patient level data were obtained from the National Cancer Data Base (NCDB) Participant User File and analyzed for demographic patterns and stage distribution (1998-2011) as well as overall survival (1998-2006). SEER, a program of the U.S. National Cancer Institute, collects cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population. NCDB, a joint program of the American College of Surgeons and the American Cancer Society, is a nationwide oncology outcomes database for more than 1,500 cancer programs in the U.S. and Puerto Rico capturing about 70% of all newly diagnosed cases of cancer in the U.S. Results: In the years 2000-2010, the overall incidence rate of EATL in the U.S. population was 0.111. Asians/Pacific Islanders had a higher incidence rate (0.236) compared to other races (whites [0.101], blacks [0.107], American Indians/Alaska natives [0.128]). The risk ratio of Asians compared to non-Asians was 2.32 (95% CI: 1.39-3.69; P =0.002). From 1998-2011, 515,026 patients were diagnosed with NHL and 337 (0.07%) had EATL. The median age was 64 years (range, 20 -90+ years) and 60% of patients were males. The stage distribution was as follows: I (26.7%), II (16.3%), III (3.3%), IV (29.1%), and unknown (24.6%). The median overall survival (OS) for the entire cohort was 5.9 months. Patients diagnosed in the more recent era (2003-2006) had a better outcome (median OS, 6.6 versus 2.6 months; Figure 1; P = 0.034). Asians/Pacific Islanders had a worse outcome compared to other races (Figure 2; P = 0.031). Multivariable analysis showed the following to be independent factors associated with inferior OS: age >60 years (HR: 1.49; 95% CI: 1.05-2.10), Asians/Pacific Islanders (HR: 2.27; 95% CI: 1.08-4.76), stage III/IV (HR: 3.03; 95%CI: 2.00-4.59), and diagnosis before 2003 (HR: 1.59; 95%CI: 1.10-2.28). Conclusions: Contrary to previous studies, we find that the highest incidence and lowest survival rates of EATL occur among Asians/Pacific Islanders, populations in which celiac disease is not considered to be prevalent. The overall survival of EATL patients has improved over time but remains poor. Figure 1 Figure 1. Figure 2 Figure 2. Disclosures No relevant conflicts of interest to declare.
Phase 1/2 Trial of a Novel CDK Inhibitor Dinaciclib (SCH727965) in Patients with Relapsed Multiple Myeloma Demonstrates Encouraging Single Agent Activity
Kumar, Shaji , LaPlant, Betsy, Zonder, Jeffrey A. , Furth, Briant, Erlichman, Charles , Stewart, Keith, Chng, Wee Joo , Callander, Natalie S. , Roy, Vivek

Mayo Clinic

Blood | October 10, 2019 | Volume: 120 | Issue: 21 | Pages: 76-76

10.1182/blood.v120.21.76.76 Get It

Abstract Abstract 76 Background: We measured proliferation in MM cells transfected with 13,984 small interfering RNAs in the absence/presence of increasing concentrations of bortezomib (BTZ) and identified 37 non lethal genes as reproducible BTZ sensitizers. The strongest hit was CDK5 a gene expressed at high levels in MM and neural tissues with relatively low expression in other organs suggesting a large therapeutic window. The small molecule CDK5 inhibitor Dinaciclib is a novel, potent, small molecule inhibitor of cyclin dependent kinases (CDK). It selectively inhibits CDK1, CDK 2, CDK 5 and CDK9 with 50% inhibitory concentrations (IC50) in the low nanomolar concentration. Based on these data, we undertook the current trial to evaluate the maximally tolerated dose of Dinaciclib in this patient population as well as assess the efficacy of single agent Dinaciclib in relapsed MM. Patients and Methods: Patients with relapsed MM and measurable disease were enrolled on this phase 1/2 trial provided they had not more than 4 prior lines of therapy for MM, had adequate performance status and organ and hematological function. Patients receiving strong inhibitors/inducers of CYP3A4 were not allowed unless the drugs could be discontinued. The primary objectives were to (i) to determine the MTD of dinaciclib in subjects with relapsed MM (phase 1) and (ii) to evaluate the confirmed response rate with dinaciclib in patients with relapsed MM (phase 2). Dinaciclib was administered on day 1 of a 21-day cycle at doses of 30–50 mg/m2. Dose escalation was done using a 3+3 design and MTD was defined as one dose level below that resulted in >=2 DLTs among 6 patients. Results: Overall, twenty-nine patients were accrued to this study (19 phase I, 10 phase II) from July 2009 to December 2011. Two patients were replaced for study violations and are not included in analysis. The Phase II analysis included the 6 patients treated at the Phase I dose level 50mg/m2 as well as the first 9 patients accrued to the Phase II portion (15 evaluable patients). The median age of the 27 evaluable patients was 66 (range, 49–81); 52% were male. The median duration from diagnosis was 42 months (range, 7–207 months); median number of prior therapies was 4 (range, 1–5). Overall, 11 (41%) patients were considered high-risk by FISH and 56% were ISS stage III at study entry. Patients have received a median of 2 cycles (range: 1–12) and all patients have discontinued treatment for disease progression (18), alternative Treatment (2), adverse Event (4), or other reasons (3). One dose limiting toxicity was seen over all dose levels. One patient at 40 mg/m2 experienced grade 3 constipation possibly related to treatment. The dose level of 50 mg/m2 was determined to be the MTD for the Phase II portion. The overall confirmed response rate was 3 of 27 (11%); including two patients at 40 mg/m2 dose (1 VGPR, 1 PR) and one patient at 50 mg/m2 dose (1 VGPR) with a PR or better. In addition, two patients at 50 mg/mg2 dose have achieved an MR; translating to an overall response rate of 18.5% (5 of 27). Figure 1 shows a waterfall plot of the M protein responses among patients with a measurable M spike. Overall, 21 patients had disease progression and 14 patients have died. Median follow-up for patients still alive is 11.8 months (range: 6.5–19.3). Leukopenia and thrombocytopenia were the most common hematological AEs, and gastrointestinal symptoms, alopecia, and fatigue, were the most common non-hematological AEs seen in the study. Conclusions: The current study demonstrates potential single agent anti-myeloma activity of dinaciclib in a relapsed MM patient population with 2 patients achieving a deep response (VGPR) and many patients obtaining some degree of M protein stabilization or decrease. Ongoing studies are examining dinaciclib in combination with proteasome inhibitors, exploring both weekly and every three-week dosing schedules. Disclosures: Zonder: Millennium Pharmaceuticals, Inc: Consultancy, Research Funding; Celgene: Research Funding.
Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes
Garcia‐Manero, Guillermo , Gore, Steven D. , Scott, Bart L. , Tefferi, Ayalew , Edenfield, William J. , Hetzer, Joel, Kumar, Keshava, Skikne, Barry, Kambhampati, Suman , Cogle, Christopher Ramin

Mayo Clinic

Blood | October 9, 2019 | Volume: 120 | Issue: 21 | Pages: 424-424

10.1182/blood.v120.21.424.424 Get It

Abstract Abstract 424 Background: Azacitidine for injection has been shown to prolong overall survival in patients (pts) with higher-risk myelodysplastic syndromes (MDS) compared with conventional care regimens (CCR) (Lancet Oncol, 2009). An oral formulation of azacitidine (CC-486) is in development. Oral azacitidine may maximize convenience, eliminate injection-site reactions, and if administered in extended dosing schedules, may enhance and prolong the therapeutic effects of azacitidine. Oral azacitidine administered once-daily (QD) for 7 days (d) of repeated 28d cycles has been shown to be bioavailable, biologically and clinically active, and well-tolerated in pts with MDS and acute myeloid leukemia (Garcia-Manero, J Clin Oncol, 2011). Preliminary evidence suggests that extending oral azacitidine dosing to 14d or 21d of the 28d cycle may enhance pharmacodynamic and epigenetic activity (Laille, Leuk Res, 2011). Purpose: To evaluate hematologic response and safety associated with extended dosing regimens of oral azacitidine in pts with lower-risk MDS. Methods: This ongoing, multicenter, phase 1 study, enrolled pts with lower-risk (IPSS Low or INT-1) MDS who were RBC transfusion dependent (TD) and/or thrombocytopenic (average platelet count ≤50,000 within 56d prior to the first dose) at baseline. Pts were sequentially assigned to receive oral azacitidine 300mg QD for either 14d or 21d of repeated 28d cycles. Hematologic assessments were made every 2 weeks. Hematologic response was assessed using IWG 2006 criteria (Cheson, Blood, 2006). Adverse events (AEs) were graded using NCI-CTCAE version 3.0. Results: At data cut-off (May 18, 2012), 53 pts with lower-risk MDS had enrolled (300mg oral azacitidine QDx14d, n=26; QDx21d, n=27). Demographic and disease characteristics at baseline were similar in the 14d and 21d treatment cohorts (Table 1). Median (range) hematology counts at baseline were Hgb 8.7 g/L (6.0–13.0), ANC 1.6×109/L (0–30.3), and platelets 56.0×109/L (6.0–564.0). At study entry, 40% of pts had received no prior MDS treatment (except transfusions), 45% had received erythropoiesis-stimulating agents, and 15% had received WBC growth factors. The number of oral azacitidine treatment cycles received ranged from 1 to 12 (median numbers of oral azacitidine cycles were 6 in the QDx14d and 4 in the QDx21d cohorts). Four pts in the 21d cohort and 1 pt in the 14d cohort received reduced oral azacitidine doses (200mg QD). Overall, 10 pts discontinued the study, including 6 pts (3 pts in each cohort) who discontinued due to AEs that may have been treatment-related (gastrointestinal [n=2] or intracranial [n=1] hemorrhage, febrile neutropenia [n=1], pneumonia [n=1], thrombocytopenia [n=1]). Overall response rates (ORR), which included complete (CR) and partial remission (PR), any hematologic improvement (HI), and transfusion independence (TI), ranged from 38.5% in the QDx14d cohort to 29.6% in the QDx21d cohort, and RBC TI was achieved by 47% and 33%, respectively, of pts who were RBC TD at baseline (Table 2). For pts who received at least 4 cycles of oral azacitidine (14d, n=19; 21d, n=14), ORR was 47.4% in the 14d and 50.0% in the 21d cohorts, and RBC TI rates in RBC TD pts (n=16) were 67% in the 14d and 57% in the 21d cohorts. The most frequent (≥5%) grade 3/4 hematologic AEs in the QDx14d cohort were anemia (11.5%), thrombocytopenia (11.5%), and neutropenia (7.7%); and in the QDx21d cohort were neutropenia (14.8%), anemia (7.4%), and febrile neutropenia (7.4%). Most frequent grade 3/4 non-hematologic AEs were gastrointestinal, including vomiting (7.7%) in the QDx14d cohort, and diarrhea (11.1%) and vomiting (7.4%) in the QDx21d cohort. Conclusions: Oral azacitidine 300mg QD administered in extended dosing schedules of 14d or 21d of repeated 28d cycles was effective and well-tolerated in these pts with lower-risk MDS. Beside hematologic AEs, the most frequently observed AEs with oral azacitidine were gastrointestinal and were manageable. Efficacy and safety outcomes with 300mg QD oral azacitidine were generally comparable between the 14d and 21d extended dosing regimens. Based on these data, oral azacitidine administered once-daily in extended dosing schedules is active and well-tolerated and warrants further investigation in randomized, controlled trials. Disclosures: Garcia-Manero: Celgene: Research Funding, Speakers Bureau. Gore:Celgene Corporation: Consultancy, Research Funding. Scott:Celgene Corporation: Honoraria, Research Funding, Speakers Bureau. Hetzer:Celgene Corporation: Employment, Equity Ownership. Kumar:Celgene Corporation: Employment, Equity Ownership. Skikne:Celgene: Employment, Equity Ownership.
Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT) have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM)
Seenithamby, Kirupananthan, Lacy, Martha Q. , Kumar, Shaji , Hayman, Suzanne R. , Litzow, Mark R. , Gastineau, Dennis A. , Inwards, David J. , Micallef, Ivana N. , Ansell, Stephen M. , Johnston, Patrick B. , Porrata, Luis F. , Patnaik, Mrinal M. , Dispenzieri, Angela , Buadi, Francis K. , Dingli, David , Hogan, William J. , Gertz, Morie A.

Mayo Clinic

Blood | October 9, 2019 | Volume: 120 | Issue: 21 | Pages: 600-600

10.1182/blood.v120.21.600.600 Get It

Abstract Abstract 600 Background: Both MM and AL are plasma cell neoplasms. The underlying clone in both diseases appears to be different not only in terms of “tumor burden” but also in terms of their underlying biology. The overall “fitness” of patients with these two diseases is also different, with AL patients having more major organ dysfunction. Therapy for both diseases is directed at killing the underlying clone. ASCT is one method of reducing the clone size and thereby improving overall survival. Post-ASCT outcomes between the two diseases have never been formally compared. Methods: We compiled all patients with a diagnosis of AL or MM who received ASCT at the Mayo Clinic Rochester between June 1996 and January 2011 to compare outcomes. Patients were retrieved from two prospectively maintained clinical transplant data bases (M.A.G.). Differences between groups were compared using Fisher's exact and Wilcoxon tests. Survival was calculated using the method of Kaplan-Meier, and differences between survival outcomes were calculated by log rank. Cox regression modeling was done to determine how non-disease specific variables—i.e. age, time period of ASCT, number of prior regimens, time to ASCT from diagnosis and acquisition of complete response (CR)—affected outcomes. All statistical analyses were performed using JMP (SAS, NC) software. This study was approved by the Mayo IRB. Results: The data set was comprised of 454 patients with AL and 1116 patients with MM. There were significant differences between the two respective groups of patients in terms of number of prior regimens (0 vs 1, p<0.0001), time to ASCT (3.95 months vs 7.20 months, p<0.0001), intensity of conditioning regimen (non-attenuated in 69.4% vs 89.1%, p<0.0001), serum creatinine (1.1mg/dl vs 1mg/dl p<0.0001), creatinine clearance (72.5 ml/minute vs 80 ml/minute p<0.0001), albumin (2.61g/dl vs 3.50g/dl, p<0.0001) CRP (0.40mg/dl vs 0.63mg/dl p<0.0001), LDH (196 U/l vs 182U/l, p<0.0001), and bone marrow plasmacytosis at transplant (6% vs 9%, p<0.0001). Hematologic response rates were also significantly different between the groups, with higher overall hematologic response in the MM group (90.9% vs 79.5%, p<0.0001) and higher complete response (CR) rates (40.1% vs 29.4%, p<0.0001) in the AL group. With a median follow-up of surviving patients of 68 months, the respective median overall survival (OS) for the AL and MM patients was 113 and 59.5 months, p<0.0001. Notably, the 5-year OS of AL and MM patients achieving CR were 91.4% and 57.7%, respectively, p<0.0001. If only those patients who were transplanted within 1 year of their diagnosis are included in the analysis, the respective 5-year OS of AL and MM patients achieving CR were 90.4% and 61.3%, p<0.0001 (Figure 1). To correct for imbalances in non-disease specific parameters, 3 multivariate analyses were performed using: 1) all patients; 2) only those achieving CR; and 3) only those who achieved a CR and were transplanted within 12 months of their diagnosis (Table 1). Among those patients achieving CR, MM patients had nearly a 4-fold risk of death as compared to patients with AL. Conclusion: Although ASCT is not available to all patients with either AL or MM, there is a significant difference in outcomes based on the diagnosis. Patients with AL who undergo ASCT enjoy a superior survival as compared MM patients undergoing the same procedure. This difference is most notable among those patients who achieve CR suggesting very different plasma cell biology between the two diseases. Disclosures: No relevant conflicts of interest to declare.
Development of Myelodysplastic Syndrome and Acute Leukemias in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS): A Population-Based Study of 17,315 Patients
Kyle, Robert A. , Kumar, Shaji , Roeker, Lindsey E. , Larson, Dirk R. , Dispenzieri, Angela , Rajkumar, S. Vincent

Mayo Clinic

Blood | October 9, 2019 | Volume: 120 | Issue: 21 | Pages: 934-934

10.1182/blood.v120.21.934.934 Get It

Abstract Abstract 934 Background: An increased risk of developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) has been observed for over 40 years in patients with multiple myeloma (MM). While treatment for MM has been implicated as the cause of excess MDS/AML, the risk may also be related to the underlying plasma cell proliferative disease process or an inherent predisposition to other hematologic malignancies in patients with plasma cell disorders. A recent study found an increased risk of AML/MDS for patients with monoclonal gammopathy of undetermined significance (MGUS) where there is no confounding chemotherapy effect to consider (Mailankody S, Blood2011; 118:4086-92). However, that report is subject to detection bias (i.e. association is related to reason for electrophoretic testing rather than the result of the test) since the population was not uniformly screened for MGUS. The purpose of this study was to determine if there was an increased risk of AML/MDS and other acute leukemias in persons with MGUS in a large population-based cohort systematically screened for the presence or absence of MGUS. Methods: The study utilized the population-based cohort established to estimate the prevalence of MGUS in the general population (N Engl J Med 2006; 354:1362-9). Serum samples were collected from 21,463 of the 28,038 residents of Olmsted County, Minnesota age 50 years or older as of 1/1/1995. Serum electrophoresis and immunofixation were used to determine MGUS status by testing all serum samples for the presence of a monoclonal protein. MGUS status was then linked to diagnoses entered in the Mayo Clinic Medical Index from 1/1/1975 to last follow up or 5/31/2006. For any patient in whom the diagnosis of AML/MDS or acute lymphoblastic leukemia (ALL) was in doubt, the diagnosis was verified by medical record review. For MGUS patients who progressed to MM or related disorder, only diagnosis of leukemia made prior to progression was considered. Results: 17,315 patients who consented to serum analysis were included in this study; blinded patients included in the original cohort could not be evaluated. The final study cohort represents 435,021 person-years of follow-up. Mean follow up for patients with MGUS (n=605) was 24.64 years (range 0.11–30.57); controls (n=16,710) had a mean follow up of 25.14 years (range 0.01–31.40). MGUS patients had a significantly higher risk of developing acute leukemia (AML/ALL) or MDS compared to controls, risk ratio 2.20 (95% CI 1.23–3.92), p=0.008 (see Table). There was a higher risk of developing AML/MDS compared to controls, risk ratio 1.80 (95% CI .09-3.59), p=0.09. The risk of developing MDS was statistically significant (RR=2.10, p=0.049). MGUS patients had a 4.18-fold increased risk of developing ALL (p=0.010) and a 2.35-fold increased risk of developing any acute leukemia (p=0.050) over the general population. In subset analysis, patients with IgA/IgG MGUS had a 1.99-fold increased risk of developing MDS (p=0.108), while patients with an IgM M spike had a 2.81-fold increased risk of developing MDS over controls (p=0.152). Though MDS was observed in patients with IgA, IgG, and IgM M-spikes, AML was only observed only in patients with IgA or IgG isotypes (n=2/484). Conclusion: Our population-based study suggests MGUS is associated with a 1.8-fold increased risk of developing MDS/AML over the general population. The risk of AML/MDS is more modest than the 8-fold increased risk suggested in a previous report (Mailankody S, Blood2011; 118:4086-92). The smaller risk ratios in our study are likely related to our population-based cohort design that uniformly screened for the presence or absence of MGUS, and thereby minimized any amplification of risk that can occur in the presence of ascertainment bias. We also found a significant increase in the risk of ALL in persons with MGUS that requires further study. Our study supports the hypothesis that there may be an inherent increased risk of acute leukemia and MDS in patients with plasma cell disorders that is independent of myeloma therapy. Disclosures: No relevant conflicts of interest to declare.